Drug Trial Radar · NCT07101627
A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy
Last checked: Nov 19, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
149
Planned (sponsor's estimate)
Start
Aug 1, 2025
Primary completion
Apr 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Jiangsu HengRui Medicine Co., Ltd.
- First posted
- Aug 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of Hetrombopag in secondary prevention of thrombocytopenia caused by lung cancer treatment
Conditions
- Lung Cancer
Interventions
Hetrombopag TabletsDrug
Stage 1: After screening and enrollment, patients will receive oral administration of hetrombopag, 7.5 mg/day, for 14 days from the first day after the end of chemotherapy in this cycle. Stage 2: Patients who met the inclusion criteria were randomized 1:1 to the experimental group and the control group after enrollment. Patients in the experimental group began to orally take hetrombopag 7.5 mg/day for 14 days on the first day after the end of chemotherapy in this cycle; patients in the control group began to orally take hetrombopag simulated tablets 7.5 mg/day for 14 days on the first day after the end of chemotherapy in this cycle. Randomization was stratified by concomitant immunotherapy (yes versus no) and chemotherapy with gemcitabine plus platinum (yes versus no).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Grade 3 and Higher ThrombocytopeniaTime frame: One cycle of treatment(21 days)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
Shanghai Pulmonary Hospital, Shanghai, China
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.